VALBIOTIS announced the appointment of Pascal SIRVENT to its Board of Directors. Pascal SIRVENT has been closely involved in the company's activity since it was created in 2014. Pascal's presence on the Board of Directors is an asset for their global strategic development, since he has a holistic vision of the context of metabolic diseases as well as precious academic knowledge acquired internationally. With over 10 years research experience, Pascal has in-depth expertise in metabolic diseases. Pascal SIRVENT was a lecturer at the University of Clermont Auvergne between 2008 and 2018, and has headed the establishment’s technical functional assessment platform since 2010. He has also set up several international scientific partnerships with Vanderbilt University (Nashville, USA), the Maine Medical Center Research Institute (Portland, Oregon, USA) and the University of Texas (Houston, USA) as part of research projects on the pathophysiology of type 2 diabetes.